Search

A gene therapy approach could prove effective at treating an inherited blood disorder called beta (β)-thalassemia.

MSK is committed to helping people with cancer live healthier, more satisfying lives during and after treatment. So that people don’t just survive cancer — they thrive.

A new study reports a possible way to quantify how efficient the immune system is at detecting cancer, and therefore how likely it is that a person will respond to immunotherapy.

Memorial Sloan Kettering (MSK)’s Department of Marketing & Communications was awarded the Silver Award for Most Effective Media Plan in the 2021 Campaign US Media Awards.

Memorial Sloan Kettering and Hackensack Meridian Health announced the Memorial Sloan Kettering–Hackensack Meridian Health partnership, a joint venture that will combine both organizations’ unparalleled expertise in all areas of cancer care and research to accelerate new discoveries and improve the lives of patients they jointly serve.

Memorial Sloan Kettering Cancer Center (MSK) announced today that physician-scientist Karuna Ganesh, MD, PhD, has been awarded a Cancer Grand Challenges grant, a prestigious global initiative that provides up to $25 million around five years to tackle the toughest problems in cancer research. Dr. Ganesh is part of an international team focused on developing new ways to “rewire” cancer cells and prevent treatment resistance in colorectal cancer, one of the leading causes of cancer-related deaths worldwide, and with rates rising among adults under 50.

A Q&A with Jaap-Jan Boelens, MD, PhD, Chief of the Pediatric Transplant and Cellular Therapy Service at MSK.

Cancer vaccines that use messenger RNA (mRNA) technology are an exciting new approach to develop immunotherapies for cancers with poor prognoses, such as pancreatic cancer.